Elena Urcelay1, Ana Isabel Sánchez-Fructuoso2, Jose Luis Santiago3,4, Luis Sánchez-Pérez1, Isabel Pérez-Flores2, Maria Angeles Moreno de la Higuera2, Natividad Calvo Romero2. 1. Laboratory of Genetics and Molecular Basis of Complex Diseases, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, IdISSC, Madrid, Spain. 2. Nephrology Department, Facultad de Medicina, Hospital Clínico San Carlos, Universidad Complutense de Madrid, IdISSC, Madrid, Spain. 3. Immunology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain. jlsantial@gmail.com. 4. Laboratory of Genetics and Molecular Basis of Complex Diseases, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, IdISSC, Madrid, Spain. jlsantial@gmail.com.
Abstract
BACKGROUND: A genome-wide association study (GWAS) in kidney transplant recipients reported the association of two polymorphisms located in the PTPRO gene and upstream of the CCDC67 (DEUP1) gene with increased risk of acute T cell-mediated rejection (TCMR). We aimed at replicating the assessment of mentioned associations and additionally ascertaining the influence of treatment and clinical features of the patients. METHODS: The polymorphisms, PTPRO-rs7976329 and CCDC67-rs10765602 were genotyped by TaqMan chemistry in 641 consecutive kidney transplant recipients. The diagnosis of rejection was confirmed by biopsy and categorized according to the Banff classification. Associations were evaluated by Chi-square test or Fisher's exact test when necessary and multivariate logistic regression. RESULTS: Considering the GWAS study we only replicated the association of the PTPRO-rs7976329*C allele in the Banff grade < II subjects. However, the homozygous mutant genotypes of both polymorphism seemed to increase the risk of TCMR Banff grade < II in the overall cohort and after stratification by Thymoglobulin induction therapy. In the multivariate analysis, we confirmed the association of PTPRO-rs7976329 with TCMR Banff grade < II, independently of the Thymoglobulin induction therapy and of CCDC67-rs10765602 only in the group of patients not receiving Thymoglobulin induction therapy. No association of these polymorphisms with TCMR Banff grade ≥ II was observed in either the overall cohort or in the subgroups stratified by Thymoglobulin therapy. CONCLUSIONS: Our study shows that the increased risk of TCMR related to polymorphisms PTPRO-rs7976329 and CCDC67-rs10765602 previously reported in a GWAS was replicated only in homozygous patients who presented TCMR Banff grade < II and for the minor allele of either polymorphism.
BACKGROUND: A genome-wide association study (GWAS) in kidney transplant recipients reported the association of two polymorphisms located in the PTPRO gene and upstream of the CCDC67 (DEUP1) gene with increased risk of acute T cell-mediated rejection (TCMR). We aimed at replicating the assessment of mentioned associations and additionally ascertaining the influence of treatment and clinical features of the patients. METHODS: The polymorphisms, PTPRO-rs7976329 and CCDC67-rs10765602 were genotyped by TaqMan chemistry in 641 consecutive kidney transplant recipients. The diagnosis of rejection was confirmed by biopsy and categorized according to the Banff classification. Associations were evaluated by Chi-square test or Fisher's exact test when necessary and multivariate logistic regression. RESULTS: Considering the GWAS study we only replicated the association of the PTPRO-rs7976329*C allele in the Banff grade < II subjects. However, the homozygous mutant genotypes of both polymorphism seemed to increase the risk of TCMR Banff grade < II in the overall cohort and after stratification by Thymoglobulin induction therapy. In the multivariate analysis, we confirmed the association of PTPRO-rs7976329 with TCMR Banff grade < II, independently of the Thymoglobulin induction therapy and of CCDC67-rs10765602 only in the group of patients not receiving Thymoglobulin induction therapy. No association of these polymorphisms with TCMR Banff grade ≥ II was observed in either the overall cohort or in the subgroups stratified by Thymoglobulin therapy. CONCLUSIONS: Our study shows that the increased risk of TCMR related to polymorphisms PTPRO-rs7976329 and CCDC67-rs10765602 previously reported in a GWAS was replicated only in homozygous patients who presented TCMR Banff grade < II and for the minor allele of either polymorphism.
Authors: A Hart; J M Smith; M A Skeans; S K Gustafson; D E Stewart; W S Cherikh; J L Wainright; A Kucheryavaya; M Woodbury; J J Snyder; B L Kasiske; A K Israni Journal: Am J Transplant Date: 2017-01 Impact factor: 8.086
Authors: L Ghisdal; C Baron; Y Lebranchu; O Viklický; A Konarikova; M Naesens; D Kuypers; M Dinic; E Alamartine; G Touchard; T Antoine; M Essig; J P Rerolle; P Merville; J L Taupin; Y Le Meur; A Grall-Jezequel; F Glowacki; C Noël; C Legendre; D Anglicheau; N Broeders; W Coppieters; E Docampo; M Georges; Z Ajarchouh; A Massart; J Racapé; D Abramowicz; M Abramowicz Journal: Am J Transplant Date: 2016-07-22 Impact factor: 8.086
Authors: Amanda Agazio; Jennifer Cimons; Kristin M Shotts; Kejun Guo; Mario L Santiago; Roberta Pelanda; Raul M Torres Journal: Front Immunol Date: 2020-07-22 Impact factor: 7.561